- Home
- STRO vs QBTS Comparison
STRO vs QBTS Comparison
Compare STRO & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- QBTS
- Stock Information
- Founded
- STRO 2003
- QBTS 1999
- Country
- STRO United States
- QBTS Canada
- Employees
- STRO 306
- QBTS N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- QBTS Retail: Computer Software & Peripheral Equipment
- Sector
- STRO Health Care
- QBTS Technology
- Exchange
- STRO Nasdaq
- QBTS Nasdaq
- Market Cap
- STRO 165.7M
- QBTS 194.5M
- IPO Year
- STRO 2018
- QBTS N/A
- Fundamental
- Price
- STRO $2.01
- QBTS $5.27
- Analyst Decision
- STRO Strong Buy
- QBTS Strong Buy
- Analyst Count
- STRO 7
- QBTS 6
- Target Price
- STRO $12.14
- QBTS $6.38
- AVG Volume (30 Days)
- STRO 984.3K
- QBTS 109.2M
- Earning Date
- STRO 11-13-2024
- QBTS 11-14-2024
- Dividend Yield
- STRO N/A
- QBTS N/A
- EPS Growth
- STRO N/A
- QBTS N/A
- EPS
- STRO N/A
- QBTS N/A
- Revenue
- STRO $160,955,000.00
- QBTS $9,424,000.00
- Revenue This Year
- STRO N/A
- QBTS $4.94
- Revenue Next Year
- STRO N/A
- QBTS $63.93
- P/E Ratio
- STRO N/A
- QBTS N/A
- Revenue Growth
- STRO 230.90
- QBTS 14.27
- 52 Week Low
- STRO $1.67
- QBTS $0.68
- 52 Week High
- STRO $6.13
- QBTS $11.41
- Technical
- Relative Strength Index (RSI)
- STRO 46.47
- QBTS 45.52
- Support Level
- STRO $1.72
- QBTS $3.74
- Resistance Level
- STRO $2.15
- QBTS $6.44
- Average True Range (ATR)
- STRO 0.14
- QBTS 1.36
- MACD
- STRO 0.05
- QBTS -0.59
- Stochastic Oscillator
- STRO 70.83
- QBTS 19.95
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is engaged in the development and delivery of quantum computing systems, software, and services, and is the commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modelling. D-Wave's annealing quantum computers are accessible through the Company's LeapTM cloud service.